Pharmaceutical Industry Reports Huntington’s Disease Treatment Market | Page 2

REPORT DESCRIPTION
Huntington’s Disease Treatment Market – Overview
Huntington's disease, also known as Huntington's chorea, is an autosomal dominant inherited rare disorder
that causes progressive degeneration of nerve cell of brain leading to deterioration of a person’s physical and
mental abilities. Huntington's disease symptoms usually are detected at the age of 30–50 and gets worse over
10 to 25 year period from the onset of disease. Huntington's disease is usually associated with movement
disorders, cognitive disorders or psychiatric disorders. Ultimately, the individual becomes susceptible to
pneumonia, heart failure or other complications causing death. Huntington's disease is preliminary diagnosed
by neurological examination, neuropsychological testing, psychiatric evaluation, genetic test, and brain
imaging and functioning. The available Huntington's disease treatment is symptomatic treatment, which
involves use of drugs such as tetrabenazine, antidepressants, antipsychotic or mood-stabilizing. Additionally,
psychotherapy, speech therapy, physical therapy, occupational therapy or lifestyle and home remedies plays
important in improving life of the patient.
Growth of the Huntington’s disease treatment market is driven by rising prevalence of disease and increasing
R&D programs by institutes and universities. According to Huntington’s disease Society of America, there
are approximately 30,000 symptomatic people in the U.S. and over 200,000 at-risk of inheriting the disease.
© Coherent market Insights. All Rights Reserved